同义名 :	FK-027; FR-17027; Trihydrate, Cefixime; Suprax; Unixime; Cefixoral; Cefixim; Cefspan; Cephoral; Cefiximum; Cefixima; CL-284635
	CAS号 :	79350-37-1
	货号 :	A467731
	分子式 :	C16H15N5O7S2
	纯度 :	97%
	分子量 :	453.45
	MDL号 :	MFCD00865020
	存储条件：	Pure form Keep in dark place, inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性
描述	Cefixime (FR-17027) is an orally active third-generation cephalosporin antibiotic, effective for treating various bacterial infections[1].[2].

临床研究
NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00926796	Gonorrhoea	Phase 4	Completed	-	United States, Alabama ... 展开 >> University of Alabama Hospital - Infectious Diseases Birmingham, Alabama, United States, 35249-0001 United States, California Los Angeles County Department of Public Health - Sexually Transmitted Disease Program Los Angeles, California, United States, 90007-2608 San Francisco Department of Public Health - San Francisco City Clinic San Francisco, California, United States, 94103-4030 United States, Maryland Johns Hopkins Bayview Medical Center - Infectious Diseases Baltimore, Maryland, United States, 21224-2735 United States, Pennsylvania Magee Women's Hospital of UPMC - Reproductive Infectious Disease Research Pittsburgh, Pennsylvania, United States, 15213-3108 收起 <<
NCT00926796	-		Completed	-	-
NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD 收起 <<

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	2.21mL 0.44mL 0.22mL	11.03mL 2.21mL 1.10mL	22.05mL 4.41mL 2.21mL

参考文献

[1]Neu HC, et al. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J. 1987 Oct;6(10):958-62. [2]Unemo M, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. [3]Matsumoto Y, et al. Antibacterial activity of cefixime against Salmonella typhi and applicability of Etest. J Infect Chemother. 1999 Sep;5(3):176-179. [4]Connolly KL, et al. Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model. Antimicrob Agents Chemother. 2019 Feb 26;63(3):e01644-18. [5]Shi Y, et al. Restoration of cefixime-induced gut microbiota changes by Lactobacillus cocktails and fructooligosaccharides in a mouse model. Microbiol Res. 2017 Jul;200:14-24. [6]Stone JW, et al. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 1989 Feb;23(2):221-8.